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Schizophrenia is a chronic condition that impacts significantly not only on the individual and family, but the
disorder also has wider consequences for society in terms of significant costs to the economy. This highly prevalent
condition affects approximately 1% of the worldwide population, yet there are few therapeutic options. The
predominant treatment strategy for schizophrenia is anti-psychotic medication (with or without additional talking
therapy) even though this approach lacks efficacy in managing the negative symptoms of the condition, is not
effective in one-third of the patient group and the side effects of the medication can be severe and debilitating. In
recent years, a number of pathophysiological processes have been identified in groups of people with schizophrenia
including oxidative stress, one-carbon metabolism and immune-mediated responses. A number of studies have shown
that these altered physiological mechanisms can be ameliorated by nutritional interventions in some individuals with
schizophrenia. This review briefly describes the aforementioned processes and outlines research that has investigated
the utility of nutritional approaches as an adjunct to anti-psychotic medication including antioxidant and vitamin B
supplementation, neuroprotective and anti-inflammatory nutrients and exclusion diets. Whilst none of these interventions
provides a ‘one-size-fits-all’ therapeutic solution, we suggest that a personalised approach warrants research attention as
there is growing agreement that schizophrenia is a spectrum disorder that develops from the interplay between
environmental and genetic factors.
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Schizophrenia is a debilitating condition that affects 1%
of the population worldwide [1]. Symptoms of schizophre-
nia are delineated into positive and negative symptoms;
the former include hallucinations, paranoia and delusions,
and examples of the latter are reduced motivation, impo-
verished speech, blunted affect and social withdrawal;
in addition this over-arching label can be further sub-
grouped based on symptom profile [2]. These symptoms
generally emerge in early adulthood and often persist in
approximately three-quarters to two-thirds of individuals
despite optimal treatment [3-5]. This enduring and/or
fluctuating course of illness leads not only to personal
distress and disability but also engenders a high societal
burden with the estimated total financial cost of £11.8
billion per annum in England alone [6]. Furthermore
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unless otherwise stated.anxiety and depressive disorders [7], asthma, chronic
obstructive pulmonary disease, type-2 diabetes and numer-
ous diabetic-related complications [8] and have increased
premature mortality due to underdiagnosed ischemic heart
disease and cancer [9,10]. Indeed, in comparison with the
general population those with schizophrenia have a two- to
three-fold higher mortality rate, which equates to a 10–25-
year reduction in life span [11]. Therefore, there is a need
to continually develop and evaluate novel treatments for
this disorder, not only for the benefit of the patients but
also for the wider society.
Currently, anti-psychotic medication (with or without
psychotherapy) is the main treatment for individuals
with schizophrenia, an intervention that led to the dopa-
mine (DA) hypothesis. This enduring theory of schizo-
phrenia has evolved over time and was first based upon
clinical observations and subsequently empirical evidence
from anti-psychotic treatment studies [12]. Briefly, in the
1970s the DA hypothesis initially pinpointed the role of
excessive dopamine in schizophrenia [13], which was latertd. This is an Open Access article distributed under the terms of the Creative
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hypodopaminergia and a subcortical hyperdopaminer-
gia [14]. However, neither of these conceptualisations
accounted for the aetiology of dopaminergic abnormality
and hence there was a further modification of the DA hy-
pothesis as a ‘final common pathway’ in which numerous
genetic and environmental factors can result in increased
presynaptic striatal dopaminergic function [15].
Although anti-psychotic medication has persisted as
the optimal treatment and is effective in managing the
positive symptoms it is limited in terms of treating
negative symptoms [16]. In addition to this drawback of
drug treatment, this type of therapy is based solely on
symptomatology and dosage is often determined by a
process of trial and error [17]. In those who respond to
anti-psychotic medication, side effects can be distressing
and often intolerable; these include involuntary movements
such as tremor and rigidity, drug induced Parkinson’s,
Tardive dyskinesia, hyper-salivation, increased heart
rate, metabolic syndrome and weight gain. Often the
side effects themselves require further pharmacological
treatment and/or result in treatment discontinuation,
leading to subsequent relapse. Furthermore, approxi-
mately one-third of individuals with schizophrenia do
not respond to anti-psychotic medication, either alone
or in conjunction with psychodynamic counselling and
other pharmacotherapy [18].
However, there is now increasing evidence that a
number of physiological mechanisms such as oxidative
stress, one carbon metabolism and atypical immune-
mediated responses exist in individuals with schizophre-
nia, not solely dopaminergic pathophysiology as per the
DA hypothesis. Furthermore, these differing pathophysio-
logical manifestations may be ameliorated by nutritional
treatment strategies. Therefore, this article aims to briefly
outline the aforementioned probable underlying con-
tributory mechanisms that have been observed in patients
diagnosed with schizophreniaa and review the research
and clinical evidence that has evaluated nutritional in-
terventions in addition to anti-psychotic medication
for schizophrenia.
Method
Only peer-reviewed studies were considered. Human
study designs included were Systematic Reviews, Rando-
mised Controlled Trials (double-blinded or otherwise),
Cohort studies, Case-Controlled studies and Case Reports.
Pubmed, Google Scholar and Science Direct were used to
search for relevant studies relating to schizophrenia and
nutrition. Additionally, references were followed up and
key papers obtained. The initial searches (replicated
across all databases) combined schizophrenia with the
following terms and their synonyms, alternate spellings
and abbreviations:1. Nutrient Searches: nutrition; Vitamin A, B (all
B-Vitamins and synonyms), C, D, E; Omega 3 and
Omega 6 Polyunsaturated fatty acids (and all
synonyms and abbreviations: e.g. EFA’s, GLA,
EPA etc.);
2. Anti-Oxidant Searches: Alpha-lipoic-acid; melatonin
3. Methylation Searches: methylation; Folate;
methyfolate; one-carbon metabolism; Vitamin
(all B-Vitamins and synonyms); Vitamin C, E;
4. Gluten Searches: Celiac Disease; Gluten Intolerance;
Gluten;
By following up the publications of key authors, N-Acetyl
Cysteine & Glutathione, and L-Theanine were identified as
relevant topics, and following two searches were added:
1. From Ritsner: L-Theanine
2. From Berk, M.S.: N-Acetyl Cysteine; Glutathione
Search terms were combined with logical ANDs as
appropriate, and were also combined with terms (with
synonyms, abbreviations and alternate spellings) describ-
ing study design to narrow search results were appropri-
ate: e.g. Randomised Controlled Trial, Cohort, etc. (Please
see Additional file 1 for details of the controlled studies
reviewed below and Additional file 2 for nutrient/drug
interactions).
Oxidative stress and the benefits of supplementation
Oxidative stress occurs when the antioxidant defence
capacity of an organism is unable to balance the produc-
tion of reactive oxygen species (ROS) and reactive nitro-
gen species (RNS), as generated from normal oxidative
metabolism [19]. There is an increasing body of evidence
demonstrating the occurrence of oxidative stress in those
with schizophrenia [20-22]. Overall, current evidence
suggests that there is a dysregulation of free radical
metabolism, specifically an alteration in the performance
of enzymatic and nonenzymatic antioxidant systems in at
least a sub-group of people with schizophrenia [20,22,23].
Additionally, oxidative stress is associated with a number
of pathophysiological mechanisms such as inflammation,
mitochondrial dysfunction, lipid peroxidation, DNA dam-
age and apoptosis and hypoactive N-methyl-D-aspartate
receptors [22-24]. Due to these findings, the benefit of
antioxidant treatment as an adjunct to standard care has
been explored in people with schizophrenia, as detailed
below.
N-acetyl cysteine (NAC)
Glutathione (GSH) is an important antioxidant and free
radical scavenger that has been found to be decreased in
the brains of people with schizophrenia [25,26]. Although
oral GSH supplementation has poor bioavailability [27],
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raise plasma glutathione levels in those with schizophrenia
[28]. In a case study of a 24-year old woman with chronic
and worsening paranoid-type schizophrenia that was
generally unresponsive to anti-psychotic treatment, the
addition of NAC supplementation improved the pa-
tient’s symptomatology in seven days. In addition to the
schizophrenia-specific symptoms, improvements were
observed in spontaneity, social skills and family rela-
tions by both the patient and family members. An RCT
including 42 participants with schizophrenia, who were
experiencing an acute phase of symptomatology, were
randomly assigned to receive up to 2 g/d of NAC plus
up to 6 mg/d of risperidone for 8 weeks as an adjunct
intervention; significant improvements in negative symp-
toms were found in the active treatment group comparted
to controls but not in positive or general psychopathology
[29]. Furthermore, a larger RCT of 140 participants ob-
served significant improvements on global symptomatol-
ogy, and general and negative symptoms of schizophrenia
in the NAC supplementation (2 g/d; in addition to anti-
psychotic medication) group in comparison to the placebo
group over a 24 week period, but not positive symptoms
[30]. Notably, after a 4-week washout period these
beneficial effects diminished, with the exception of
clinical severity scores.
Alpha lipoic acid (ALA)
Alpha lipoic acid (ALA) is another powerful antioxidant
which crosses the blood brain barrier and performs
similar functions to GSH. Early work in the 1950s
showed promise with ALA supplementation [31]. More
recent research has focused on the side effects of trad-
itional anti-psychotic medication such as weight gain. For
instance, Kim et al. [32] proposed that ALA may amelior-
ate weight gain by modulating adenosine monophosphate-
activated protein kinase activity in the hypothalamus and
peripheral tissues in those with schizophrenia who are
prescribed anti-psychotic therapy as this enzyme is in-
volved with cellular energy homeostasis [33]. In a case
series of five individuals with schizophrenia given
supplemental ALA, after 12 weeks participants lost a
statistically significant amount of weight, total choles-
terol levels were reduced and heightened energy was
reported by 60% of the sample; however, the symptoms
of schizophrenia did not improve from baseline to
follow-up [32]. Hence, in this limited data, ALA may
be beneficial in counteracting some of the potentially
distressing side effects of anti-psychotic medication,
which may in turn help with treatment compliance.
Furthermore, in a commentary on the topic Seybolt en-
courages the scientific community to focus on genetic
sub-groups (e.g. responders and non-responders) so that
targeted ALA treatment may be developed specifically forresponders in order to reduce symptomatology and in-
crease functional ability [34].
Melatonin (N-acetyl-5-methoxytryptamine)
Melatonin (N-acetyl-5-methoxytryptamine) is a naturally
occurring compound that plays an important role in the
sleep-wake cycle (circadian rhythm) and is also a powerful
antioxidant as a direct free radical scavenger and stimula-
tor of antioxidant enzymes [35]. In addition, melatonin
enhances intracellular glutathione (GSH) and stabilizes
cellular membranes [35]. The nocturnal secretion of mela-
tonin has been found to be decreased in drug-free patients
with schizophrenia and this did not improve following
anti-psychotic drug treatment [36-38]. This may explain
at least partially why insomnia is a commonly reported
peripheral symptom in schizophrenia [39]. In terms of
supplementation, a small RCT of 19 patients evaluated
the effectiveness of melatonin as an addition to standard
medical care over seven weeks [40]. It was found that
sleep efficiency significantly improved in those receiving
the melatonin supplement and furthermore was most
effective in people with the worst sleep efficiency. Simi-
larly in a larger RCT of 40 participants, those in the
melatonin augmented group reported improved sleep
quality and also heightened freshness on awakening, im-
proved mood, and improved daytime functioning [41].
Although these improvements in sleep quality may not
directly impact the predominant symptoms of schizophre-
nia, heightened functioning and improved mood are still
notable findings for this difficult-to-treat condition. Fi-
nally, in a systematic review of the literature, Anderson
and Maes go so far as to suggest that the reduced secre-
tion of melatonin contributes to the aetiology and patho-
physiology in patients with schizophrenia and should be
considered in treatment approaches not only to manage
symptoms but also to control for the metabolic side ef-
fects of anti-psychotic medication [42].
The latter is because some anti-psychotics, in particular
olanzapine, decrease melatonin which may account for
the metabolic dysregulation and weight gain experienced
by patients taking these medications [43]. Indeed, in an
RCT including both schizophrenia and bipolar disorder
patients, melatonin was added to second generation anti-
psychotic treatment over an eight-week period to establish
whether melatonin could attenuate the adverse metabolic
effects produced by these medications [44]. Compared to
placebo, the melatonin group saw improvements in dia-
stolic blood pressure and attenuated weight gain, although
individuals with bipolar disorder observed the strong
beneficial metabolic effects of melatonin on fat mass.
Vitamins C and E
Vitamins C (ascorbic acid) and E (a-tocopherol) are non-
enzymatic dietary antioxidants which may be beneficial in
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break free radical-chain reactions [45]. In a double-blind
RCT, 40 patients with schizophrenia were tested for serum
malondialdehyde (MDA; a marker of lipid peroxidation)
and plasma ascorbic acid at baseline and eight weeks fol-
lowing supplementations with vitamin C [46]. High levels
of serum MDA and low plasma ascorbic acid were found
in the sample as a whole but at follow-up normalisation of
these markers were observed only in the group receiving
vitamin C as an adjunct to anti-psychotic treatment.
Schizophrenic symptomatology also improved significantly
in the experimental group compared to those receiving a
placebo. Early studies showed promising findings in relation
to the benefits of Vitamin E for the treatment of tardive
dyskinesia (TD) [47-50]. However a recent meta-analysis of
11 RCTs concluded that there is no evidence that Vitamin
E improves established TD; although there were limited
findings illustrating that Vitamin E supplementation can
prevent TD from deteriorating [51]. Therefore, adding
Vitamin E to treatment protocols may still be of some
benefit to patients experiencing this distressing symptom
that can arise from long-term use of anti-psychotic drugs.
Essential polyunsaturated fatty acids (PUFAs)
Fatty acids constitute approximately 50-60% of the dry
weight of an adult human brain, of which 35% is made
up of essential polyunsaturated fatty acids (EPUFAs) [52].
EPUFAs are important components of the phospholipids
that comprise specialised cell membranes which play a
central role in the physiology and function of the brain
[53]. EPUFAs have been hypothesised as an aetiological
factor in schizophrenia as early as the 1990s [54] due to
findings of low levels of EPUFAs in the red blood cell
membranes [55,56] and brains of those with schizophrenia
[57,58]. In addition to oxidative stress, there have been
various other suggestions as to why levels of EPUFAs are
decreased in people with schizophrenia including altered
neuronal membrane metabolism [59] and/or dysregula-
tion of the inflammatory response system [60]. Even
though the exact mechanism behind the reduced levels of
EPUFAs is under debate, there have been numerous stud-
ies investigating the effectiveness of EPUFA supplementa-
tion in patients with schizophrenia. For example, in young
adults presenting with sub-threshold psychotic states, a
12-week omega-3 EPUFA supplementation programme
consisting of 700 mg of eicosapentaenoic acid (EPA),
480 mg of docosahexaenoic acid (DHA), 220 mg of other
omega-3 EPUFAs (18:3n3, 18:4n3, 20:4n3, 21:5n3, and
22:5n3) plus 7.6 mg of mixed tocopherol (Vitamin E) low-
ered the risk of symptoms developing into a psychotic dis-
order, as compared to placebo [61]. In older adults with
schizophrenia lower levels of red blood cell membrane
fatty acids were found at baseline in comparison to con-
trols [62]. These levels increased significantly at 4-monthfollow-up after omega-3 EPUFA supplementation com-
bined with vitamin C and E and were associated with
improvements in psychopathology and quality of life.
Importantly in this study, participants with schizophrenia
were matched with health controls on age, sex, ethnicity,
diet and lifestyle patterns so the differences in baseline
levels of EPUFAs were not due to group differences [62].
A recent review has suggested that because levels of fatty
acids have been shown to be decreased in the brains of
individuals with schizophrenia, and since this type of sup-
plementation exhibits low risk of harm, the addition of
EPUFAs to standard medical care for those with schizo-
phrenia may be beneficial [63].
L-Theanine
L-Theanine (gamma-glutamylethylamide) is an amino
acid found in tea plants and may be beneficial due to its
antioxidant activity, namely its ability to effectively inhibit
peroxidation [64] and diminish the doxorubicin-induced
adverse reactions involved in oxidative damage [65].
Furthermore, L-Theanine has also been investigated as
an adjunct therapeutic supplement for people with
schizophrenia. In an 8-week double-blind randomised
placebo-controlled study which included 40 participants
diagnosed with schizophrenia or schizoaffective disorder,
it was found that compared with placebo, augmentation of
antipsychotic therapy with L-Theanine was associated
with reduction of anxiety, positive and general psycho-
pathology, compared to placebo [66]. However, negative
symptomatology, objective neurocognitive functioning,
general functioning, quality of life and side effect
prevalence did not differ in the groups. In terms of the
mechanism of this supplement, circulating levels of
neurochemical indicator brain-derived neurotrophic
factor (BDNF) and cortisol-to-dehydroepiandrosterone
sulphate (DHEAS)*100 molar ratio appear to be associ-
ated with the observed clinical improvements in schizo-
phrenia symptoms, although the exact reason for this
relationship is unclear [67]. Miodownik et al. postulate
that alterations in serum BDNF level and cortisol-to-
DHEAS*100 molar ratio may mediate the beneficial ef-
fects of L-Theanine augmentation. As L-Theanine was
found to be safe and well tolerated in the trial [66],
there appears to be justification for its use; however
larger scale studies and replications are warranted to
further clarify the role of this amino acid in the treatment
of schizophrenia.
One carbon metabolism and B vitamins
The original observation that certain aberrant methylated
compounds can affect mental state was proposed in the
1950s [68] and later refined into the one-carbon cycle
hypothesis of schizophrenia [69]. Methylation reactions are
now recognised to have an immensely complex influence
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widespread biochemical mechanism [70]. Furthermore,
elevated levels of homocysteine (a toxic amino acid
produced in excess during abnormal methylation pro-
cesses [71]) have been observed in individuals with schizo-
phrenia [72]. The key areas proposed as factors in the
aetiology of schizophrenia with links to one carbon
metabolism include faulty/abnormal DNA synthesis,
gene regulation, membrane fluidity, synaptic function,
and neurotransmitter synthesis [70,73-75].
Folate and B vitamin supplementation
The metabolism of folate is a central mechanism in one
carbon metabolism where it interacts with the methionine
cycle and transmethylation reactions [76]. Studies measur-
ing serum folate levels in patients with schizophrenia have
consistently found significantly lower levels in those with
the disorder compared to control participants [77-79].
However, these low levels may not be exclusively due to
dietary intake as recent work has found associations in
variants of four genes linked to folate metabolism where
low-functioning genetic variants were associated with
increased negative symptom severity [80]. Therefore,
Roffman et al. suggest that folate supplementation as an
adjunct to anti-psychotic therapy may be of benefit in
those with a genetic susceptibility [80]. An early RCT of
supplementation with methylfolate in addition to standard
treatment illustrated clinical improvements in people with
schizophrenia or major depression (33% of which had bor-
derline or definitive folate deficiency) over a 6-month
period [81]. In a large scale RCT of 140 participants with
schizophrenia, Roffman et al. randomized patients to
either folic acid (2 mg) and vitamin B12 (400 mcg) or pla-
cebo for 16 weeks. The active treatment group showed
improvement in negative symptoms but only when geno-
types that were previously associated with negative symp-
tom severity were taken into account. [82]. Similarly, the
benefits of folate supplementation on negative symptoms
were only revealed once the sample was sub-grouped by
genotype; those patients who had at least one copy of the
low-functioning variant of the methylenetetrahydrofolate
reductase (MTHFR) gene showed a greater improvement
in negative symptoms compared to the placebo group. In-
deed this variant has been associated with the onset of
schizophrenia [83].
Folate supplementation has also been shown to reduce
homocysteine levels in individuals with schizophrenia. In
a randomised, double-blind, placebo-controlled, cross-
over design, patients with elevated homocysteine levels
were given oral folic acid, B-12, and pyridoxine for three
months, followed by a placebo [84]. Homocysteine levels
decreased during the supplement phase of the study and
were associated with clinical improvements in symp-
tomatology and neurocognitive performance. Therefore,adjunct treatment with B vitamins appears promising in
those with high homocysteine levels and also in people
with a genetic predisposition to abnormal folate metabol-
ism. Indeed, Roffman et al. [80] propose that genotyping
based on specific genes that play crucial roles in the folate
metabolism pathway and also broader systems of methyla-
tion may lead to targeted nutritional treatment strategies
for those with schizophrenia.
Immune-mediated responses and the therapeutic benefits
of casein- and gluten-free diets
Celiac disease (CD) is an immune-mediated condition
that leads to inflammation of the small intestinal mucosa
resulting in damage, loss of absorptive villi and ultimately
nutrient malabsorption [85]. CD is triggered by gliadin, a
protein found in wheat gluten, and other alcohol-soluble
proteins (prolamines) contained in barley and rye [86].
Elimination of gluten restores intestinal mucosa, resolves
symptoms and improves quality of life [86,87]. The link
between schizophrenia and CD in children and young
adults was observed in clinical settings as early as the
1950s and 60s [88,89]. A recent population-based case-
controlled study which estimated the lifetime prevalence
of a range of autoimmune disorders in schizophrenia
found that those with the condition were 3.6 times more
likely to be diagnosed with CD than healthy matched con-
trols [90]. In a review of the epidemiological evidence,
Kalaydjian et al. noted that the average prevalence of CD
in those with schizophrenia across eleven studies was
2.6%, which is higher that the estimated 1% of diagnosed
cases of CD in the general population [91]. However,
research has identified that the anti-gliadin immune re-
sponse in schizophrenia may have a different antigenic
specificity, being independent of the action of transgluta-
minase enzyme that is found in those with CD [92]. In
some individuals with schizophrenia and other psychiatric
conditions such as anxiety, depressive and mood disor-
ders, attention deficit hyperactivity disorder (ADHD) and
autism spectrum disorders, CD and gluten sensitivity are
possibly involved in the disruption of intestinal permeabil-
ity and immunologic abnormalities, leading to neurologic
and psychiatric symptomatology [93].
Exclusion diets as an adjunct to anti-psychotic medication
A number of studies have found significant symptom
resolution following the introduction of a gluten-free diet
for patients with schizophrenia, in addition to standard
care. Early work by Dohan found clinical improvements in
62% of male patients who received a milk- and cereal-free
diet [94]. The patients on this diet were moved from a
locked in-patient setting to an open ward after an average
of seven days; in comparison, only 36% of the men on a
high-cereal diet were fit to be moved to a less secure set-
ting in this timeframe. A follow-up study replicated these
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free diets moved from the locked to the open ward twice
as quickly as the patient who consumed high cereal foods
[95]. Tellingly, when gluten was added to the experimental
diet (without patients’ or staffs’ knowledge) the effects
disappeared in both studies. Analogous findings were ob-
served in 14 participants who were given a milk- and
cereal-free diet for six weeks and subsequent blind wheat
challenge [96]. The improvements in 30 out of 30 mea-
sures of psychopathy, social avoidance and participation
diminished when gluten was introduced to the diet but
returned with the wheat was removed again. However
other studies have shown either mixed or non-significant
results [97-101], inferring that exclusion diets may only be
beneficial for a sub-group of people with schizophrenia.
Furthermore, as with all the interventions outlined in this
paper, the introduction of exclusion diets should only be
considered as an add-on to traditional pharmacological
treatment.
Vitamin D as a risk factor for the development of
schizophrenia
It has been hypothesized that low prenatal vitamin D is
a risk factor for the incidence of adult-onset schizophre-
nia as the lack of this fat-soluble vitamin and steroid
hormone may detrimentally impact on the developing
foetal brain [102]. Research using animal models has
shown that low prenatal vitamin D alters brain develop-
ment [103]. Epidemiological data such as season of birth
(higher prevalence of people with schizophrenia have
been observed to be born in winter months [104]), urban
birth [105], higher rates of schizophrenia in migrant
groups [106] and prenatal malnutrition [107] have been
cited as support for this hypothesis [108,109]. In a large-
scale birth cohort study of 9,114 people in Finland, the
use of vitamin D supplements in the first year of life was
associated with a reduced risk of developing schizophrenia
at 31 years of age, with higher doses seen as more benefi-
cial than lower amounts [110]. This finding was, however,
only observed in men, not women. Conversely in a study
looking at women only, those with the highest dietary
intake of Vitamin D had a 37% lower risk of developing
psychotic-like symptoms compared to women with the
lowest intake, when controlling for age, total energy in-
take, country of birth, BMI and dietary intake of vitamin
B12 [111]. However, there is evidence that high doses of
vitamin D are not necessarily protective; in 424 matched
pairs from a population-based cohort, a bi-modal relation-
ship appeared in which the participants with the lowest
and highest levels of vitamin D had increased risk of
schizophrenia. Therefore, the relationship between vita-
min D and schizophrenia needs further investigation, even
though a recent review of the evidence concluded that ad-
equate levels of vitamin D are needed for normal braindevelopment and function and furthermore that at-risk
groups should be offered supplementation [112].
Conclusion
Schizophrenia is a devastating, complex and disabling dis-
order of which current orthodox treatment (anti-psychotic
medication with or without psychodynamic or other forms
of talking therapy) has limited efficacy in some patients and
is often accompanied by severe side effects which require
further medication, leading to poor compliance. This re-
view has highlighted a number of possible contributory
mechanisms including oxidative stress, one carbon metab-
olism, essential fatty acid insufficiency and immune-
mediated responses that have been observed in individuals
with schizophrenia, and documented the nutritional inter-
ventions that have been proposed to modify these aberra-
tions. Nutritional strategies offer promise as an adjunct to
pharmacological therapy and pose little risk of harm to pa-
tients. However, it must be noted that the likelihood of a
‘one size fits all’ nutritional intervention for the treatment
of schizophrenia is slim due to the heterogeneity of the
underlying pathophysiology in the condition. Therefore, a
more beneficial approach for treating individuals with
schizophrenia could be personalised medicine, of which
nutritional therapy could play an important part. Within
this individualised treatment a patient would be first tested
for any deficiencies and physiological abnormalities docu-
mented in this paper, with the goal of amending these atyp-
ical findings via diet alteration and supplementation. We do
not know of any published studies which evaluate such an
approach although this type of treatment is offered by spe-
cialised private clinics. Future research should attempt to
robustly evaluate such a personalised approach as it appears
that schizophrenia may be a spectrum of disorders, rather
than a discrete disorder with identical biochemical mecha-
nisms and symptomatology, possibly due to the interplay of
environmental and genetic influences. Furthermore, add-
itional research aimed at identifying genetic variants asso-
ciated with disturbances of biological pathways should be
carried out to increase our understanding of this complex
disorder and guide individualised treatment programmes.
Endnote
aPlease note that this review does not claim to review
the biochemical and physiological pathways of these
mechanisms in depth as this is outside the scope of the
article. Please refer to the reference list for further infor-
mation on each mechanism included in this paper.
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